# Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions

> **NCT00778557** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL

## Key facts

- **NCT ID:** NCT00778557
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2005-06
- **Final completion:** 2005-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2008-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00778557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00778557, "Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00778557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*